Position in SVRA
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$403,390
+$157,873 QoQ
Shares Held
73,881
+81.5% QoQ
Ownership
0.036%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#87
of 184 holders
Holding Since
Dec 2023
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in SVRA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026EntryPoint Capital, LLC holds $19,484,871 across 56 Biotechnology names. SVRA ranks #19 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TBPH |
Theravance Biopharma, Inc.
|
49,739 | $807,263 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
3,922 | $783,027 | |
| 3 | ADMA |
Adma Biologics, Inc.
|
83,961 | $756,488 | |
| 4 | VCEL |
Vericel Corp
|
22,674 | $729,422 | |
| 5 | HRMY |
Harmony Biosciences Holdings, Inc.
|
24,264 | $679,634 | |
| 6 | UPB |
Upstream Bio, Inc.
|
73,568 | $662,112 | |
| 7 | INCY |
Incyte Corp
|
6,483 | $610,179 | |
| 8 | RARE |
Ultragenyx Pharmaceutical Inc.
|
26,119 | $547,193 |
All Filings in SVRA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $403,390 | 73,881 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $245,517 | 40,716 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $291,483 | 81,648 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $406,980 | 178,500 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $503,184 | 181,655 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $317,094 | 103,288 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $173,683 | 40,963 | Shares | Sole | 2024-11-13 | |
| 2024-03-31 | $79,117 | 15,887 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $214,522 | 45,643 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||